HC Wainwright Estimates enGene’s Q1 Earnings (NASDAQ:ENGN)

enGene Holdings Inc. (NASDAQ:ENGN) – Equities researchers at HC Wainwright lowered their Q1 2026 earnings estimates for shares of enGene in a research note issued on Tuesday, December 23rd. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.65) per share for the quarter, down from their prior forecast of ($0.64). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for enGene’s Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($2.84) EPS, FY2027 earnings at ($2.60) EPS, FY2028 earnings at ($1.60) EPS, FY2029 earnings at ($0.83) EPS and FY2030 earnings at $0.61 EPS.

Several other research analysts have also recently issued reports on the stock. Oppenheimer reiterated an “outperform” rating and set a $33.00 target price (up from $30.00) on shares of enGene in a report on Wednesday, November 12th. Raymond James Financial raised shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective on the stock in a report on Tuesday, November 11th. Morgan Stanley boosted their price objective on shares of enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 12th. UBS Group increased their target price on enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a research report on Wednesday, November 12th. Finally, Citigroup reiterated a “market outperform” rating on shares of enGene in a report on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $22.38.

enGene Stock Performance

Shares of enGene stock opened at $9.45 on Thursday. The company has a current ratio of 6.30, a quick ratio of 10.34 and a debt-to-equity ratio of 0.09. The stock’s fifty day moving average price is $7.92 and its 200-day moving average price is $5.86. The firm has a market cap of $609.94 million, a P/E ratio of -4.12 and a beta of -0.28. enGene has a 12 month low of $2.65 and a 12 month high of $11.14.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Monday, December 22nd. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.18).

Hedge Funds Weigh In On enGene

Several institutional investors and hedge funds have recently bought and sold shares of the company. Cresset Asset Management LLC acquired a new stake in enGene in the second quarter worth about $36,000. Paloma Partners Management Co acquired a new position in shares of enGene during the second quarter valued at about $38,000. PFS Partners LLC purchased a new position in shares of enGene in the 3rd quarter valued at approximately $61,000. Raymond James Financial Inc. boosted its stake in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in enGene in the 3rd quarter worth approximately $76,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene, Inc is a clinical?stage biopharmaceutical company focused on the development of gene?based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off?target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.